Prevalence of Human Papillomavirus, Cytomegalovirus and Chlamydia trachomatis among Women with Normal Cervical Cytology and their Impact on TLRs Expression

R. Enthumathi, S. Shanmughapriya, S. Sumathi, B.C. Das and K. Natarajaseenivasan

Medical Microbiology Laboratory, Department of Microbiology, Centre for Excellence in Life Sciences, Bharathidasan University, Tiruchirappalli, 620024, Tamilnadu, India

Department of Gynecology, KAPV Medical College, Tiruchirapalli, 620001, Tamilnadu, India

Amity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University Uttar Pradesh Campus, Noida, 201313, India

Corresponding Author: K. Natarajaseenivasan, Medical Microbiology Laboratory, Department of Microbiology, Centre for Excellence in Life Sciences, Bharathidasan University, Tiruchirapalli, 620024, Tamilnadu, India Tel: +914312407082 Fax: +9194312407045

ABSTRACT

To study the prevalence of HPV infection and its associated co-infection among sexually active women with normal cytology and to correlate the infection status with TLR expression. In a population based study, first voided urine samples were collected from 370 sexually active women with normal cervical cytology. The presence of HPV, CMV and CT infections were by PCR based approach. The expression pattern of TLR2 and TLR4 was analyzed in formalin fixed cervical tissue samples by immunohistochemistry. An overall HPV, CMV and CT prevalence of 22.6, 6.8 and 2.3%, respectively was reported among the study population. Further it was observed that women with HPV infections were more prone to CMV (OR: 1.79, 95% CI 0.69-4.63) and CT (OR: 22.41, 95% CI 2.65-189.48) infections. The immunostaining of the formalin fixed blocks with anti-TLR2 and TLR4 showed surface expression of TLRs in cervical squamous with no infection and TLR2 and TLR4 immunoreactivity in infected cervical samples were markedly negative. The infection of the cervix with HPV, CMV and CT decreases TLR2 and TLR4 expression in cervical squamous and thus abolishes the innate immune responses. The abolished TLR response may be a crucial step in the carcinogenic events mediated by infectious agents.

Key words: HPV, normal cytology, prevalence, TLR2, TLR4

INTRODUCTION

Cancer of the uterine cervix is the second most common cancer among women worldwide. It is the leading cancer among Indian women and considered as a serious public health problem of global importance (Gheit et al., 2009, 2014; Bhatla and Maheswari, 2009). Epidemiological and experimental data have shown cervical cancer to be linked to infection with certain genotypes of Human Papilloma Virus (HPV) (Van Tine et al., 2004). Acquisition of HPV is especially common among young sexually active women with 3-year cumulative incidence estimated to be more than 40% (Ho et al., 1998; Woodman et al., 2007). A cross-sectional evaluation of the HPV prevalence in 13 countries estimated that 6.6% of women in the age range of 15-74 years with normal cytology are carriers of HPV DNA, with marked variation within and between world regions range (1.4-25.6%). The crude and adjusted HPV prevalence estimates in 157879 women
with normal cytology, stratified by 15 world regions showed crude HPV prevalence among women with normal cytology to be 10%. The corresponding adjusted prevalence estimate was 10.4, 95% CI 10.2-10.7 (Vinodhini et al., 2012a).

However, most HPV infections spontaneously regress and only in a small percentage of cases the infection persists and causes low-grade intraepithelial lesions (LSIL) that progress to high-grade intraepithelial lesions (HSIL) and ultimately, develop into invasive cervical carcinoma (Hariri et al., 2012). It is now accepted that persistent infection by high-risk HPVs is a necessary but nonsufficient condition for the development of cervical cancer (Burd, 2003). Several epidemiological studies have shown concurrent bacterial or viral infections with increased HPV persistence to be closely associated to the progression of cervical carcinoma.

Cytomegalovirus (CMV), a herpesvirus frequently infects the cervix and produces persistent infections of the genitourinary tract. *Chlamydia trachomatis* (CT) infection was examined as a cause of Invasive Cervical Cancer (ICC) among women with HPV infection. The infection with CT has been observed to increase the risk of squamous cervical cancer among HPV-positive women. Generally, CMV and CT are found to be the predominant co-infecting partners of HPV. Thus the presence of CT and CMV co-infections might promote HPV persistence or enhance its oncogenicity. With this view point sexually active women with normal cervical cytology were screened for the presence of HPV infection and for their co-infections with CMV and CT. Further studied whether persistent infection of the cervix epithelium induces TLR-mediated immune response which might be a critical cofactor for the development of cervical lesions.

**MATERIALS AND METHODS**

**Study sites:** A population based study was conducted as a part of our screening program to estimate the prevalence of HPV and its associated co-infections including CT and CMV among sexually active women with normal cytology from three taluks (Musiri, Mannachanallur and Tiruchirapalli) of Tiruchirappalli district, Tamilnadu, India between January 2013 and April 2013.

**Study subjects:** Approximately 120 first voided urine samples were collected from each stratum (taluk) making a total of 370 samples from sexually active women aged between 20 and 65 years. Apart from this, three cervical biopsy samples from women undergoing hysterectomy for reasons other than anogenital tract cancers and confirmed to have normal pathology were collected from Annal Mahatma Gandhi General Hospital, Tiruchirapalli and was used as control. The inclusion criteria for the study subjects were: (1) Negative diagnosis for any kind of cancer, (2) No history of hysterectomy or cervical colonization, (3) No physical or mental problems, (4) not pregnant, (5) not received antibiotics for the past six months. The study has been approved by the Institutional Ethics Committee of Bharathidasan University (DM/07/101/373).

**Sample collection:** To reach women from each stratum, collaboration with the local health care centers and Governmental Hospitals was set up. The public health nurses invited participation by visiting women at home and informed them about the risk factors, prevention, early detection and pretreatment of cervical carcinoma. The purpose and procedures of the study were explained to study subjects and informed written consent was obtained from all the participants. The women who gave consent to participate were included and visual inspection of the cervix was done for all participating women and a smear was diagnosed by cytoscreeners to confirm normal cytology. First voided urine samples were collected from participants in a 50 mL falcon tubes and the samples
were immediately transported to lab on ice. The samples were refrigerated and stored at 4°C before processing. The women included in the study were interviewed for characteristics such as age, age at first sexual intercourse, number of sexual partners, number of pregnancies and paan (Betal leaf combined with areca nut cured tobacco) chewing habits.

**Sample processing:** The collected urine samples were centrifuged at 3000 g for 20 min. After centrifugation the supernatant was discarded and the resultant cell pellets were washed twice in ice-cold 1X PBS and stored at -20°C until use. The collected biopsy samples were placed immediately in ice cold PBS and transported to the laboratory on ice and stored at -20°C until use. DNA was extracted from cellular pellets by guanidium thiocyanate method (Thilagavathi et al., 2012) and from biopsy samples by phenol-chloroform method (Vinodhini et al., 2012b). To test the integrity of DNA obtained, a PCR for human genomic β-globulin gene using specific primers was performed.

**Detection of HPV, CMV and CT infection:** A PCR based detection for HPV, CMV and CT infection was adopted (Shanmughapriya et al., 2012). The DNA samples were tested by the MY09/11 PCR protocol. The samples negative for MY09/11 were further assessed for the presence of HPV DNA with general GP5+/6+ PCR system. CT infection was detected by a nested PCR based assay using KL5/KL6 and KL1/KL2 primers complementary to sequence of the cryptic plasmid. CMV infection was detected by a nested PCR based assay using external and internal primers specific for CMV glycoprotein B gene. The expected product size of 150, 350 and 150 bp for HPV, CT and CMV respectively was visualized on a 2% agarose gel stained with ethidium bromide.

**Immunohistochemistry:** Immunohistochemistry analysis was performed to correlate the status of TLR responses in cervical tissues during the studied bacterial and viral infections. Immunohistochemistry using formalin fixed paraffin embedded tissue blocks corresponding to the biopsy samples used for PCR based detection was carried out. The sections were deparaffinised followed by antigen retrieval (autoclave retrieval at 121°C for 10 min in 10 mM sodium citrate buffer, pH 6.0). Polyclonal antibodies to TLR-2 and TLR-4 (Biovision, USA) was diluted in 1:50 in blocking solution and reacted overnight at 4°C. An anti-mouse IgG HRP detection system with diaminobenzidine tetrachloride (Sigma Aldrich, USA) was used. The sections were counter stained with hematoxylin and embedded. The results of immunohistochemistry were interpreted as strongly positive (+3) only when >10% of the tumour cells demonstrated a strong complete membrane staining as weakly positive (+2) when weak to moderate complete membrane staining was observed in >10% of the tumour cells and as negative (0/+1) when a barely perceptible or no membranous staining was observed.

**Data analysis:** All data were reviewed for completeness at the end of each interview. The data were coded and analyzed using the SPSS package version 11.0. Univariate analysis was undertaken to screen potentially significant risk variables for HPV, CMV and CT infections. The odds ratio and the corresponding 95% confidence intervals were calculated by unconditional logistic regression and maximum likelihood estimation. Tests of statistical significance were based on difference in the log likelihoods and all p values are 2-sided.

**RESULTS**

A total of 370 first voided urine samples were obtained from women who met the inclusion criteria. Of the 370 samples, 47 missed the cellular pellets and hence discarded. DNA was extracted
from the remaining 323 samples and the quality of the DNA was analyzed on a 0.8% agarose gel stained with ethidium bromide. The integrity of the extracted DNA samples was analyzed by PCR for the β-globulin gene. Of the 323, 13 samples were excluded because they were found negative for β-globulin. The final study group comprised of 310 women with no abnormal cervical cytology.

The GP5+/6+PCR based analysis to study the prevalence of HPV infection among 310 women showed 70 (22.6%) samples to be positive for HPV infection, with Manachanallur showing the highest prevalence of 27.2%, followed by Musiri (25.2%) and Tiruchirapalli (11.5%). The nested PCR based analysis to study the prevalence of CMV infection showed 21 (6.8%) to be positive, with Tiruchirapalli showing the highest prevalence of 10.3%, followed by Musiri (7.2%) and Manachanallur (3.7%). Among 310 samples, 7 (2.3%) were CT positive, with Manachanallur showing the highest prevalence of 3.7%, followed by Musiri (2.4%) and none from Tiruchirapalli (Table 1).

Table 2 summarizes the major factors associated with HPV infection. Early age at first coitus (OR 2.67, 95% CI 0.95-7.38), being never pregnant (OR 3.08, 95% CI 0.89-10.57), pan chewing (OR 3.59, 95% CI 0.70-18.42) and nulliparity (OR 2.05, 95% CI 0.57-7.32) showed significant association with HPV infection.

The study was extended to evaluate CMV and CT co-infections among HPV positive women. To examine mutual relationships between HPV and CMV or HPV and CT infections, we calculated Odds Ratios (ORs) with their 95% confidence intervals (95% CI). Accordingly we found that women with HPV infections (10%, 7/70) were more likely to be co-infected with CMV than those without HPV infections (5.6%, 14/240), with an odds ratio of 1.79 (95% CI 0.69-4.63). Similarly CT co-infection was more predominant among women with HPV infections (8.6%, 6/70) than those without HPV infections (0.42%, 1/240), with an odds ratio of 22.41 (95% CI 2.65-189.48) (Table 3).

Next we hypothesized whether persistent bacterial and viral infection of the cervical epithelium induces TLR2 and TLR4-mediated inflammation, a critical cofactor for cervical lesion. To analyze the correlation between different bacterial and viral infection with TLR2 and TLR4 response the formalin fixed samples from patients undergoing hysterectomy for reasons other than anogenital cancer were used. The corresponding fresh biopsy samples of the formalin fixed blocks were analyzed for HPV, CMV and CT infection by PCR based approach as described earlier. Of the three samples analyzed one each were found to be positive for none, HPV and HPV/CMV infection. The immunostaining of the formalin fixed blocks with anti-TLR2 and anti-TLR4 showed surface expression of TLR2 and TLR4 in cervical squamous with no infection (Fig. 1a). Surprisingly no staining with TLR2 and TLR4 was detected in cervical columnar epithelial cells infected with HPV alone as well as in HPV and CMV co-infection (Fig. 1b and c). TLR2 and TLR4 immunoreactivity in infected cervical samples was markedly negative. Although sample size was limited, the differences of TLR2 and TLR4 expression levels between normal cervical epithelia with no infection and with various bacterial and viral infections was found to be statistically significant (p<0.001).

Table 1: Prevalence of HPV, CMV and CT infections among women with normal cervical cytology

| Types of infection | Musiri (n = 125) | Manachanallur (n = 107) | Tiruchirapalli (n = 78) | Over all (n = 310) |
|-------------------|----------------|-------------------------|-------------------------|------------------|
|                   | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative |
| HPV               |         |          |          |          |          |          |          |          |
|                   | No.     | %       | No.     | %       | No.     | %       | No.     | %       |
|                   | 31      | 25.0    | 94      | 75.0    | 30      | 27.8    | 77      | 72.2    |
|                   | 9       | 11.5    | 70      | 88.5    | 9       | 11.5    | 89      | 90.4    |
|                   | 22.6%   |          | 77.4%   |          | 22.6%   |          | 77.4%   |          |
| CMV               |         |          |          |          |          |          |          |          |
|                   | No.     | %       | No.     | %       | No.     | %       | No.     | %       |
|                   | 9       | 7.1     | 116     | 92.9    | 4       | 4.2     | 103     | 95.8    |
|                   | 8       | 9.6     | 70      | 90.4    | 8       | 9.6     | 90      | 90.4    |
|                   | 0.42%   |          | 99.6%   |          | 0.42%   |          | 99.6%   |          |
| CT                |         |          |          |          |          |          |          |          |
|                   | No.     | %       | No.     | %       | No.     | %       | No.     | %       |
|                   | 3       | 2.4     | 122     | 97.6    | 4       | 4.2     | 103     | 95.8    |
|                   | 0       | 0.0     | 78      | 100.0   | 7       | 2.4     | 100     | 100     |
|                   | 2.3%    |          | 97.7%   |          | 2.3%    |          | 97.7%   |          |
Table 2: Risk factors associated with HPV infection among sexually active women with normal cervical cytology

| Parameters           | HPV positive (n = 70) | HPV negative (n = 240) | OR   | 95% CI  |
|----------------------|-----------------------|------------------------|------|---------|
| **Occupation**       |                       |                        |      |         |
| House Wife           | 36                    | 100                    | 51.4 | 41.6    | 1.46   | 0.76-2.81 |
| Manual Laborer       | 22                    | 96                     | 31.4 | 40.0    | 0.69   | 0.39-1.21 |
| Others               | 12                    | 44                     | 17.2 | 18.4    | 0.90   | 0.46-1.86 |
| **Age at first coitus** |                      |                        |      |         |
| <15                  | 10                    | 15                     | 14.3 | 6.3     | 2.64   | 0.95-7.38 |
| 16-20                | 27                    | 156                    | 38.6 | 65.0    | 0.33   | 0.17-0.65 |
| 21-25                | 33                    | 69                     | 47.1 | 28.8    | 1.52   | 0.74-3.1  |
| **No of pregnancies**|                       |                        |      |         |
| 0                    | 8                     | 9                      | 11.4 | 3.7     | 3.08   | 0.89-10.57*|
| 1-3                  | 46                    | 152                    | 65.7 | 63.4    | 1.00   | Ref      |
| >3                   | 16                    | 79                     | 22.9 | 32.9    | 0.62   | 0.29-1.32 |
| **Sexual intercourse**|                       |                        |      |         |
| Often                | 21                    | 67                     | 30.0 | 28.0    | 1.09   | 0.54-2.33 |
| Rare                 | 49                    | 173                    | 70.0 | 72.0    | 1.00   | Ref      |
| **No of sexual partner** |                     |                        |      |         |
| 0-1                  | 66                    | 225                    | 94.3 | 93.8    | 1.00   | Ref      |
| >2                   | 4                     | 15                     | 5.7  | 6.2     | 1.03   | 0.27-3.91 |
| **Abortion**         |                       |                        |      |         |
| Yes                  | 21                    | 76                     | 30.0 | 31.7    | 0.83   | 0.41-1.71 |
| No                   | 49                    | 164                    | 70.0 | 68.3    | 1.00   | Ref      |
| **Cervical screening**|                       |                        |      |         |
| Yes                  | 4                     | 12                     | 5.7  | 5.0     | 1.00   | Ref      |
| No                   | 66                    | 228                    | 94.3 | 95.0    | 0.77   | 0.2-3.01 |
| **Pan chewing**      |                       |                        |      |         |
| Yes                  | 4                     | 5                      | 5.7  | 1.9     | 3.59   | 0.70-18.42*|
| No                   | 66                    | 235                    | 94.3 | 98.1    | 0.28   | 0.05-1.48 |
| **Menopause**        |                       |                        |      |         |
| Yes                  | 15                    | 36                     | 21.4 | 14.9    | 1.54   | 0.68-3.51 |
| No                   | 55                    | 204                    | 78.6 | 85.1    | 1.00   | Ref      |
| **Types of delivery**|                       |                        |      |         |
| Normal               | 55                    | 203                    | 78.6 | 84.5    | 0.65   | 0.29-1.49 |
| Cesarean             | 15                    | 37                     | 21.4 | 15.5    | 1.53   | 0.67-3.49 |
| **No of Children**   |                       |                        |      |         |
| 0                    | 6                     | 10                     | 8.6  | 4.3     | 2.05   | 0.57-7.32*|
| 1-2                  | 48                    | 148                    | 68.6 | 61.5    | 1.00   | Ref      |
| >3                   | 16                    | 82                     | 22.9 | 34.2    | 0.59   | 0.28-1.25 |

Table 3: Correlation between HPV and CMV infection and HPV and CT infection among women with normal cervical cytology

| Other infections | Positive (n = 70) | Negative (n = 240) | OR   | 95% CI  |
|------------------|-------------------|--------------------|------|---------|
| **CMV**          |                   |                    |      |         |
| Positive (n = 21)| 7                 | 14                 | 1.79 | 0.64-4.63|
| Negative (n = 289)| 63                | 226                |     |         |
| **CT**           |                   |                    |      |         |
| Positive (n = 7) | 6                  | 1                  | 22.86 | 2.70-193.33 |
| Negative (n = 303)| 64                | 239                |     |         |

DISCUSSION

The development of HPV vaccines holds tremendous promise in developing countries like India where cervical cancer is the most common malignancy among middle-aged women, particularly in rural areas. By the effort and under the auspices of the Indian Council of Medical Research (ICMR) HPV vaccination trial is being carried out in India. To maximize the cost effectiveness of the HPV vaccination programmes in India, it is important to understand the prevalence of HPV infection
in various geographical regions. In this regard, as a part of our surveillance in Tiruchirapalli district we sought to evaluate the prevalence of HPV infection among sexually active women with normal cytology from three major taluks of Tiruchirapalli district.

The present population based screening showed an overall HPV prevalence of 22.6%, which is comparably greater than two large populations based screening from Osmanabad District of West India (10.3%) and Dindigul district of South India (9.6%) (Sankaranarayanan et al., 2005, 2009; Franceschi and Mahe, 2005). Thus envisaging an increase in the prevalence of HPV infection among women and hence Tiruchirapalli can be classified as region with high HPV prevalence according to Clifford et al. (2005).

We then asked whether the sexually active women have other bacterial and viral co-infections with HPV. As expected women with HPV infections were more prone to CMV and CT infections with an odds ratio of 1.79 (95% CI 0.69-4.63) and 22.41 (95% CI 2.65-189.48) respectively. Thus it can be postulated that HPV infection is necessary but nonsufficient to develop invasive cervical carcinoma. Our results have been well supported by several epidemiological studies that show concurrent bacterial or viral infections with increased HPV persistence to be closely associated to the progression of cervical carcinoma. The CMV has been isolated from cell cultures derived from biopsies of cervical carcinomas (Melnick et al., 1978) and has been shown to induce transformation of cells in vitro (Albrecht and Rapp, 1973; Geder et al., 1976). In some seroepidemiological studies, a higher frequency of circulating antibodies against CMV has been found in women with cervical carcinoma than in women with other cancers or without malignant disease (Vestergaard et al., 1972). Similarly CT infection was examined as a cause of Invasive Cervical Cancer (ICC) among women with HPV infection. CT increased the risk of squamous cervical cancer among HPV-positive
women. Case-control studies for HPV infection status have demonstrated an association between detection of antibodies to CT and the development of cervical cancer (Anttila et al., 2001; Koutsky et al., 1992; Wallin et al., 2002), providing considerate evidence for this hypothesis. A retrospective study demonstrated an increased risk of cervical cancer in women who had a history of CT infection (Wallin et al., 2002).

After considering the cervix of sexually active women to be infected with various bacterial and viral infections we next explored whether their persistent infection could trigger TLR immune response. Thus it is important to determine TLRs' effects on preneoplasia CINs and cervical cancer. In the present study, demonstrated TLR2 and TLR4 expression to be down regulated during infection of the cervical epithelium with CMV, CT or HPV.

The mammalian TLRs are key components in the innate immune response to infection and play a crucial role in the defense against microbial invasion. Several studies has shown TLR4 to be induced during viral and bacterial infections (Ramphal et al., 2008; Wieland et al., 1998; Song et al., 2007a, b; Tulic et al., 2007; Delgado-Lopez and Horwitz, 2006). Consistent with the previous study we initially expected TLR2 and TLR4 to be induced in response to bacterial and viral infection of the cervical epithelium and TLR2 and TLR4-mediated inflammation might be a critical cofactor for cervical lesion. But to our surprise, we observed a down-regulation of TLR2 and TLR4 expression. Our observations are supported by several findings, where TLR9 expression has been suppressed in HPV16-positive cancer-derived cell lines and primary cervical cancers. The suppressive effect was mainly attributed to HPV16 E6 and E7 proteins that inhibited TLR9 transcription (Hasan et al., 2007). Furthermore, our study has also been substantiated by a report where Hepatitis B Virus (HBV) is able to suppress the TLR-induced antiviral activity of liver cells (Wu et al., 2009). However, current evidence indicates TLR4 gene expression is decreased in leukemic leukocyte populations (Webb et al., 2009).

CONCLUSION
The observation of the present study suggest that in addition to the screening for prevalence of HPV infections, CMV and CT infection should be investigated as an essential predisposing factor for cervical cancer. In addition, cervical cancer development is linked to the persistent infection of high-risk HPVs. Thus E6 and E7 the major oncoproteins of HPV play a key role in the tumorigenesis of cervical epithelium. An unknown mechanism can be used by HPV to suppress the host immune response probably by deregulating TLRs transcript. This indicates the innate immune responses to be abolished and thus may be a crucial step in the carcinogenic events mediated by HPVs. But the regulation of TLR expression in tumors has not been fully elucidated and the current evidence is controversial. Hence further studies have to be carried out to study the expression of TLRs in human cells with various bacterial and viral infections.

ACKNOWLEDGMENT
Dr. KNS greatly acknowledge the Indian Council of Medical Research (ICMR) New Delhi for funding the research (5/13/88/06/NCD-III).

REFERENCES
Albrecht, T. and F. Rapp, 1973. Malignant transformation of hamster embryo fibroblasts following exposure to ultraviolet-irradiated human cytomegalovirus. Virology, 55: 53-61.
Anttila, T., P. Saikku, P. Koskela, A. Bloigu and J. Dillner et al., 2001. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. J. Am. Med. Assoc., 285: 47-51.
Bhatla, N. and N.D. Maheswari, 2009. HPV screening for cervical cancer in rural India: Do we have an answer? Natl. Med. J. India, 22: 183-184.

Burd, E.M., 2003. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev., 16: 1-17.

Clifford, G.M., S. Gallus, R. Herrero, N. Munoz and P.J.F. Snijders et al., 2005. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: A pooled analysis. Lancet, 366: 991-998.

Delgado-Lopez, F. and M.S. Horwitz, 2006. Adenovirus RIG-1alphabeta complex inhibits lipopolysaccharide signaling without altering TLR4 cell surface expression. J. Virol., 80: 6378-6386.

Franceschi, S. and C. Mahe, 2005. Human papillomavirus testing in cervical cancer screening. Br. J. Cancer, 92: 1591-1592.

Geder, K.M., R. Lausch, F. O’Neill and F. Rapp, 1976. Oncogenic transformation of human embryo lung cells by human cytomegalovirus. Science, 192: 1134-1137.

Gheit, T., S. Vaccarella, M. Schmitt, M. Pawlita and S. Franceschi et al., 2009. Prevalence of human papillomavirus types in cervical and oral cancers in Central India. Vaccine, 27: 636-639.

Gheit, T., B. Abedi Ardekani, C. Carreira, C.G. Missad, M. Tommasino and M.C. Torrente, 2014. Comprehensive analysis of HPV expression in laryngeal squamous cell carcinoma. J. Med. Virol., 86: 642-646.

Hariri, S., M. Steinau, A. Rinas, J.W. Gargano and C. Ludema et al., 2012. HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001-2006. PLoS ONE, Vol. 7. 10.1371/journal.pone.0034044

Hasan, U.A., E. Bates, F. Takeshita, A. Biliato and R. Accardi et al., 2007. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol., 178: 3186-3197.

Ho, G.Y., A.S. Kadish, R.D. Burk, J. Basu, P.R. Palan, M. Mikhail and S.L. Romney, 1998. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int. J. Cancer, 78: 281-285.

Koutsky, L.A., K.K. Holmes, C.W. Critchlow, C.E. Stevens and J. Paavonen et al., 1992. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med., 327: 1272-1278.

Melnick, J.L., R. Lewis, I. Wimberly, R.H. Kaufman and E. Adam, 1978. Association of cytomegalovirus (CMV) infection with cervical cancer: Isolation of CMV from cell cultures derived from cervical biopsy. Intervirology, 10: 115-119.

Ramphal, R., V. Balloy, J. Jyot, A. Verma, M. Si-Tahar and M. Chignard, 2008. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J. Immunol., 181: 586-592.

Sankaranarayanan, R., B.M. Nene, K.A. Dinshaw, C. Mahe and K. Jayant et al., 2005. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int. J. Cancer, 116: 617-623.

Sankaranarayanan, R., B.M. Nene, S.S. Shastri, K. Jayant and R. Muwonge et al., 2009. HPV screening for cervical cancer in rural India. N. Engl. J. Med., 360: 1385-1394.

Shanmugapriya, S., G. Senthilkumar, K. Vinodhini, B.C. Das, N. Vasanthi and K. Natarajaseenivasan, 2012. Viral and bacterial aetiologies of epithelial ovarian cancer. Eur. J. Clin. Microbiol. Infect. Dis., 31: 2311-2317.

Song, J., B.L. Bishop, G. Li, M.J. Duncan and S.N. Abraham, 2007a. TLR4-initiated and cAMP-mediated abrogation of bacterial invasion of the bladder. Cell Host Microbe, 1: 287-298.
Song, J., M.J. Duncan, G. Li, C. Chan, R. Grady, A. Stapleton and S.N. Abraham, 2007b. A novel TLR4-mediated signaling pathway leading to IL-6 responses in human bladder epithelial cells. PLoS Pathog., Vol. 3. 10.1371/journal.ppat.0030060

Thilagavathi, A., S. Shanmughapriya, K. Vinodhini, B.C. Das and K. Natarajaseenivasan, 2012. Prevalence of Human Papillomavirus (HPV) among college going girls using self collected urine samples from Tiruchirappalli, Tamilnadu. Arch. Gynecol. Obstetr., 286: 1483-1486.

Tulic, M.K., R.J. Hurrelbrink, C.M. Prele, I.A. Laing and J.W. Upham et al., 2007. TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide. J. Immunol., 179: 132-140.

Van Tine, B.A., L.D. Dao, S.Y. Wu, T.M. Sonbuchner and B.Y. Lin et al., 2004. Human Papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning. Proc. Natl. Acad. Sci. USA., 101: 4030-4035.

Vestergaard, B.F., A. Hornsleth and S.N. Pedersen, 1972. Occurrence of herpes- and adenovirus antibodies in patients with carcinoma of the cervix uteri. Measurement of antibodies to herpesvirus hominis (types 1 and 2), cytomegalovirus, EB virus and adenovirus. Cancer, 30: 68-74.

Vinodhini, K., S. Shanmughapriya, B.C. Das and K. Natarajaseenivasan, 2012a. Prevalence and risk factors of HPV infection among women from various provinces of the world. Arch. Gynecol. Obstetr., 285: 771-777.

Vinodhini, K., S. Shanmughapriya, S. Sanmugham, G. Senthikumar, B.C. Das and K. Natarajaseenivasan, 2012b. Prevalence of high-risk HPV and associated risk factors in cases of cervical carcinoma in Tamil Nadu, India. Int. J. Gynecol. Obstetr., 119: 253-256.

Wallin, K.L., F. Wiklund, T. Luostarinen, T. Angstrom and T. Anttila et al., 2002. A population based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int. J. Cancer, 101: 371-374.

Webb, R.N., J.M. Cruse and R.E. Lewis, 2009. Decreased TLR4 gene expression in leukemic leukocyte populations. Exp. Mol. Pathol., 87: 117-126.

Wieland, U., G.E. Gross, A. Hofmann, N. Sohendra, H.P. Berlien and H. Pfister, 1998. Novel Human Papillomavirus (HPV) DNA sequences from recurrent cutaneous and mucosal lesions of a stoma-carrier. J. Invest. Dermatol., 111: 164-168.

Woodman, C.B., S.I. Collins and L.S. Young, 2007. The natural history of cervical HPV infection: Unresolved issues. Nat. Rev. Cancer, 7: 11-22.

Wu, N., F. Liu, H. Ma, F.X. Zhu and Z.D. Liu, 2009. HBV infection involving in hepatic progenitor cells expansion in HBV-infected end-stage liver disease. Hepatogastroenterology, 56: 964-967.